TITLE:
Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer

CONDITION:
Breast Cancer

INTERVENTION:
111In-DAC

SUMMARY:

      The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when
      used with planar and SPECT imaging for the detection of breast cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients will be eligible for the study if they:

          -  Are non-pregnant, non-lactating females 18 years of age or older(must agree to use an
             appropriate and effective method of birth control during the study and for 2 weeks
             after study)

          -  Are being evaluated for a known or suspected breast tumor (must present with either a
             mammographic abnormality 10mm or larger or a mammographically occult but palpable
             abnormality of the breast)

          -  Have been previously scheduled for biopsy or surgical excision of the known or
             suspected tumor of the breast

          -  Have signed an informed consent form

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have a history or suspicion of significant allergic reaction or anaphylaxis to any of
             the 111In-DAC components

          -  Have a clinically unstable medical condition or opportunistic infection, a
             life-threatening disease state, impaired renal or hepatic function or are
             immunosuppressed

          -  Are taking or have taken part in any investigational study within 30 days of start of
             study

          -  Have received an indium agent within 30 days of start of study

          -  Are not able to remain immobile during scanning time

          -  Have taken drugs that may damage the kidneys within 2 weeks of start of study

          -  Have abnormal laboratory test results: hemoglobin < 9.5 gms/dl, serum creatinine >
             1.5 mg/100ml, alkaline phosphatase 2X the upper limit of normal

          -  Have undergone an excisional and/or needle localization biopsy within 4 days prior to
             start of study
      
